Conference Reports

16 March 2019 - 17 March 2019
San Francisco, California
14 February 2019 - 16 February 2019
19 January 2019 - 20 January 2019
San Francisco, California
17 January 2019 - 19 January 2019
San Antonio, Texas
04 December 2018 - 08 December 2018
San Diego, California, US
01 December 2018 - 04 December 2018
Singapore
23 November 2018 - 25 November 2018
Kuala Lumpur
22 November 2018 - 25 November 2018
Munich
19 October 2018 - 23 October 2018
Kuala Lumpur
01 October 2018 - 04 October 2018
Amsterdam, the Netherlands
23 July 2018 - 27 July 2018
Stockholm, Sweden
14 June 2018 - 17 June 2018
Chicago, Illinois
01 June 2018 - 05 June 2018
05 May 2018 - 06 May 2018
Chicago, Illinois, US
14 April 2018 - 18 April 2018
Barcelona, Spain
21 March 2018 - 23 March 2018
Geneva
11 April 2018 - 14 April 2018
Copenhagen
16 March 2018 - 19 March 2018
San Francisco, California
08 February 2018 - 10 February 2018
San Francisco, California, US
18 January 2018 - 20 January 2018
Hong Kong
20 January 2018 - 20 January 2018
Atlanta, Georgia, US
09 December 2017 - 12 December 2017
San Antonio, Texas, US
05 December 2017 - 09 December 2017
Singapore
17 November 2017 - 19 November 2017
San Diego, California, US
24 September 2017 - 27 September 2017
Madrid, Spain
08 September 2017 - 12 September 2017
Madrid
22 June 2017 - 25 June 2017
Chicago, Illinois, US
02 June 2017 - 06 June 2017
Geneva
05 May 2017 - 08 May 2017
Orlando, Florida
16 February 2017 - 18 February 2017
Amsterdam
27 January 2017 - 30 January 2017
Singapore
16 December 2016 - 19 December 2016
San Diego, California
03 December 2016 - 06 December 2016
San Antonio, Texas
06 December 2016 - 10 December 2016
Vienna
04 December 2016 - 07 December 2016
Copenhagen
07 October 2016 - 11 October 2016
Singapore
20 July 2016 - 24 July 2016
Chiang Mai
13 May 2016 - 15 May 2016
Geneva
13 April 2016 - 16 April 2016
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers.